The fusion protein between dCas9 and transcriptional activator VP160 could drastically increase the expression level of dystrophin homolog utrophin via targeting its promoters [122,123], which represents a promising compensatory approach for DMD treatment. The gene discussed is UTRN; the disease is Duchenne muscular dystrophy.